Novo Nordisk (NOVOb.CO) said on Monday that an older oral version of its semaglutide drug failed to meet its primary endpoint in late-stage trials evaluating whether the medicine could slow cognitive decline in patients with early-stage Alzheimer’s disease, sending the company’s shares down 10%.
24 Nov 2025-16:15
